AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation - PubMed (original) (raw)

Affiliations

PMID: 7514242

AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation

R Kusec et al. Leukemia. 1994 May.

Abstract

The chromosomal translocation t(8;21)(q22;q22) in acute myeloid leukemia (AML) can be detected by a reverse transcription-polymerase chain reaction (RT-PCR) for the chimeric AML1/ETO transcript. We have evaluated the clinical relevance of this method for monitoring and detection of minimal residual disease (MRD) in seven patients who reached a complete hematological remission (CHR) after chemotherapy or autologous bone marrow transplantation (ABMT). Peripheral blood (PB) samples of five patients in first continuous complete remission (CCR) were still PCR-positive at a frequency of 1 in 10(5) cells after 7, 8, 8, 10 or 66 months. Chemotherapy led to a reduction from first- to second-step PCR-positivity in three serially monitored patients. AML1/ETO mRNA was also detected in the PB of two patients in CCR, 10 or 12 months after ABMT. PB and bone marrow (BM) showed identical results in all samples tested simultaneously. AML1/ETO fusion transcripts were neither found in the PB and BM of a healthy individual, nor in the PB of a patient after allogeneic BMT for cytogenetically proven t(8;21)-leukemia. Our results indicate the presence of cells carrying the AML1/ETO rearrangement in the PB and BM of all patients in CHR after chemotherapy or ABMT for t(8;21)-positive AML. While this finding raises interesting questions about the biology of acute leukemia, it limits the value of the AML/ETO RT-PCR for the prediction of impending relapse.

PubMed Disclaimer

Cited by

The molecular detection of circulating tumour cells.
Johnson PW, Burchill SA, Selby PJ. Johnson PW, et al. Br J Cancer. 1995 Aug;72(2):268-76. doi: 10.1038/bjc.1995.324. Br J Cancer. 1995. PMID: 7640205 Free PMC article. Review. No abstract available.
Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1-ETO mouse model.
Cabezas-Wallscheid N, Eichwald V, de Graaf J, Löwer M, Lehr HA, Kreft A, Eshkind L, Hildebrandt A, Abassi Y, Heck R, Dehof AK, Ohngemach S, Sprengel R, Wörtge S, Schmitt S, Lotz J, Meyer C, Kindler T, Zhang DE, Kaina B, Castle JC, Trumpp A, Sahin U, Bockamp E. Cabezas-Wallscheid N, et al. EMBO Mol Med. 2013 Dec;5(12):1804-20. doi: 10.1002/emmm.201302661. Epub 2013 Oct 4. EMBO Mol Med. 2013. PMID: 24124051 Free PMC article.
Insights into the molecular profiles of adult and paediatric acute myeloid leukaemia.
Aung MMK, Mills ML, Bittencourt-Silvestre J, Keeshan K. Aung MMK, et al. Mol Oncol. 2021 Sep;15(9):2253-2272. doi: 10.1002/1878-0261.12899. Epub 2021 Feb 11. Mol Oncol. 2021. PMID: 33421304 Free PMC article. Review.
Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice.
Fenske TS, Pengue G, Mathews V, Hanson PT, Hamm SE, Riaz N, Graubert TA. Fenske TS, et al. Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15184-9. doi: 10.1073/pnas.0400751101. Epub 2004 Oct 11. Proc Natl Acad Sci U S A. 2004. PMID: 15477599 Free PMC article.
Clinical significance of minimal residual disease in childhood acute myeloid leukemia.
Miyamura T, Sakata N, Okamura T, Yasui M, Inoue M, Yagi K, Sako M, Komada Y, Matsuyama T, Oda M, Park YD, Kawa K. Miyamura T, et al. Int J Hematol. 2004 Apr;79(3):243-9. doi: 10.1532/ijh97.03113. Int J Hematol. 2004. PMID: 15168592

AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation - PubMed (original) (raw)